πŸ‡ΊπŸ‡Έ FDA
Patent

US 12398154

Azaquinazoline pan-KRas inhibitors

granted A61PA61P35/00

Quick answer

US patent 12398154 (Azaquinazoline pan-KRas inhibitors) held by Mirati Therapeutics, Inc. expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
49
CPC classes
A61P, A61P35/00